Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

被引：0
作者：
Ayako Fuchigami
Fumika Shigiyama
Toru Kitazawa
Yosuke Okada
Takamasa Ichijo
Mariko Higa
Toru Hiyoshi
Ikuo Inoue
Kaoru Iso
Hidenori Yoshii
Takahisa Hirose
Naoki Kumashiro
机构：
[1] Toho University Graduate School of Medicine,Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine
[2] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Division of Diabetes, Endocrinology and Metabolism
[3] University of Occupational and Environmental Health,The First Department of Internal Medicine, School of Medicine
[4] Saiseikai Yokohamashi Tobu Hospital,Department of Diabetes and Endocrinology
[5] Japanese Red Cross Medical Center,Division of Diabetes and Endocrinology
[6] Saitama Medical University,Department of Endocrinology and Diabetes, School of Medicine
[7] Japan Community Health Care Organization Tokyo Kamata Medical Center,Department of Internal Medicine
[8] Juntendo Tokyo Koto Geriatric Medical Center,Department of Medicine, Diabetology and Endocrinology
来源：
Cardiovascular Diabetology | / 19卷
关键词：
Type 2 diabetes; Cardiometabolic risk factors; Dapagliflozin; Sitagliptin; Glycemic control; Weight loss; Hypoglycemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 285 条
[1]  
Ogurtsova K(2017)IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040 Diabetes Res Clin Pract 128 40-50
[2]  
da Rocha Fernandes JD(1998)Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229-234
[3]  
Huang Y(2015)Excess mortality among persons with type 2 diabetes N Engl J Med 373 1720-1732
[4]  
Linnenkamp U(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[5]  
Guariguata L(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[6]  
Cho NH(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357
[7]  
Haffner SM(2013)Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 1327-1335
[8]  
Lehto S(2013)Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 1317-1326
[9]  
Ronnemaa T(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242
[10]  
Pyorala K(2013)Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 2508-2515
12345678910